Sodium channel blockers are known to be effective for muscle stiffness in patients with a mutation in the SCN4A gene encoding Nav1.4 and for muscle cramps in amyotrophic lateral sclerosis (ALS) patients.3,4. This evidence concerns the gene SCN4A and amyotrophic lateral sclerosis.